TNFSF10 and neoplasm: Active targeting of TRAIL to cancer cells by fusion with an antibody moiety targeting a tumor-associated antigen enriched in tumor cells results not only in increased accumulation of the fusion proteins at the tumor site, but also mimics membrane-bound presentation of TRAIL, thus allowing higher efficacy and less inflammatory response.